Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

被引：0
作者：
Rachelle S Doody
Rema Raman
Reisa A Sperling
Eric Seimers
Gopalan Sethuraman
Richard Mohs
Martin Farlow
Takeshi Iwatsubo
Bruno Vellas
Xiaoying Sun
Karin Ernstrom
Ronald G Thomas
Paul S Aisen
机构：
[1] Baylor College of Medicine,Alzheimer’s Disease and Memory Disorders center, Department of Neurology
[2] Department of Neurosciences,Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine
[3] University of California San Diego,Department of Neurosciences
[4] University of California San Diego,Department of Neurology
[5] Harvard Medical School,Eli Lilly & Company
[6] Lilly Corporate Center,Department of Neurology
[7] Indiana University,Graduate School of Medicine
[8] Indiana Alzheimer Disease Center,Gerontopole UMR INSERM 1027
[9] University of Tokyo,Biostatistics Research Center, Department of Family and Preventive Medicine
[10] CHU,Alzheimer’s Disease Cooperative Study, Department of Family and Preventive Medicine
[11] University of Toulouse,undefined
[12] University of California San Diego,undefined
[13] Department of Neurosciences,undefined
[14] University of California San Diego,undefined
来源：
Alzheimer's Research & Therapy | / 7卷
关键词：
Amyloid Precursor Protein; Amyloid Precursor Protein Cleavage; Notch Cleavage; Adverse Event Category; Uric Acid Reduction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 86 条
  • [1] Hardy J(2002)The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6. A published erratum appears in Science. 297 2209-79
  • [2] Selkoe DJ(2008)Disease-modifying therapies in Alzheimer’s disease Alzheimers Dement. 4 65-390
  • [3] Salloway S(1998)Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein Nature. 391 387-2564
  • [4] Mintzer J(2009)Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA. 302 2557-693
  • [5] Weiner MF(2012)A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects Clin Pharmacokinet. 51 681-1440
  • [6] Cummings JL(2012)Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease Arch Neurol. 69 1430-54
  • [7] De Strooper B(2009)A γ-secretase inhibitor decreases amyloid-β production in the central nervous system Ann Neurol. 66 48-97
  • [8] Saftig P(2006)γ-secretase inhibitors for Alzheimer’s disease: balancing efficacy and toxicity Drugs R D 7 87-522
  • [9] Craessaerts K(1999)A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain Nature. 398 518-350
  • [10] Vanderstichele H(2013)A phase 3 trial of semagacestat for treatment of Alzheimer’s disease N Engl J Med. 369 341-198
123456789